FDA wants more Bydureon data

FDA issued a second complete response letter for an NDA from Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) for Bydureon exenatide once weekly that could result in a delay of 18 months or more for the

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE